The company is betting that the alternative cytotoxic payload in its ADC can overcome resistance in patients who relapse on Enhertu.

The phase 3 trial compares trastuzumab deruxtecan (Enhertu; AstraZeneca, Daiichi Sankyo) in combination with pertuzumab (Perjeta, Genentech) vs. current first-line standard of care in patients ...

CHICAGO — Trastuzumab deruxtecan plus pertuzumab showed significant improvement in PFS compared with taxane chemotherapy plus trastuzumab and pertuzumab across patients with HER2-positive ...

The best UI/UX design bootcamps provide an accelerated pathway into the field of web and app development and design. Many of these programs offer beginner-friendly training that moves from the ...

Amplification of the human epidermal growth factor receptor 2 (HER2, Erb B2) gene leads to persistent activation of signaling pathways that enhance cell proliferation, resistance to apoptosis signals, ...

And then for the patients who were taking trastuzumab deruxtecan, you could stop if you had toxicity, and in the pertuzumab arm, add trastuzumab as a maintenance approach.

"Following the promising results seen in our earlier phase trial, IDeate-Prostate01 has been initiated to evaluate whether ifinatamab deruxtecan may replace standard taxane-based chemotherapy as a ...

Does your outdoor space need a makeover? Maybe you’ve been researching landscape design ideas and are considering hiring a landscape architect or designer. Maybe you hope to learn more about the ...

IDeate-Prostate01 phase 3 clinical trial of ifinatamab deruxtecan began in patients with pretreated metastatic castration-resistant prostate cancer ...

The combination of trastuzumab deruxtecan (T-DXd; Enhertu) and pertuzumab (Perjeta) extended progression-free survival (PFS) by nearly 14 months compared with the current first-line standard of care.

As practicing oncologists, we can get bogged down in our individual practices and thus have trouble seeing the bigger picture ...